{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:34:32Z","timestamp":1790865272177,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2007,10,22]],"date-time":"2007-10-22T00:00:00Z","timestamp":1193011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Both hepatitis B and hepatitis C viruses (HBV and HCV) cause chronic infections worldwide that are associated with development of liver diseases ranging from mild liver inflammation to hepatocellular carcinomas. While efficient preventive vaccines are available for HBV, efforts are ongoing to develop one in case of HCV. Yet, both infections share the fact that therapeutic agents available to treat already established infections are yet poorly efficient, toxic or associated with development of resistance. Thus, novel immune\u2010based therapies are actively being developed to complement or replace standard antiviral treatments. Among those, development of therapeutic vaccines represents a major effort. Peptide\u2010, recombinant protein\u2010 or viral vector\u2010based vaccines have been engineered and tested at preclinical and clinical levels. Means to adjuvant these vaccines are being pursued, including approaches based on combining vaccines of different nature. This review will outline major advances in the field of both HBV and HCV therapeutic vaccine development with a particular focus on candidates presented at the 12th International Symposium on Viral Hepatitis and Liver Disease (July 2006, Paris, France).<\/jats:p>","DOI":"10.1111\/j.1365-2893.2007.00922.x","type":"journal-article","created":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T04:21:53Z","timestamp":1193199713000},"page":"97-103","source":"Crossref","is-referenced-by-count":35,"title":["Vaccines and immunotherapies against hepatitis B and hepatitis C viruses"],"prefix":"10.1111","volume":"14","author":[{"given":"G.","family":"Inchausp\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.13.040195.000333"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119559"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70289-1"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.3.1047"},{"issue":"6","key":"e_1_2_7_6_2","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1128\/jvi.69.6.3358-3368.1995","article-title":"Activation of a heterogeneous hepatitis B (HB) core and e antigen\u2010specific CD4+ T\u2010cell population during seroconversion to anti\u2010HBe and anti\u2010HBs in hepatitis B virus infection","volume":"69","author":"Jung MC","year":"1995","journal-title":"J Virol"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115280"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.9.5863"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(00)00109-0"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1573"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.11.5707-5719.2004"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.6.3322-3328.2005"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.739"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250233"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.6.3447"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21162"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.10.1395"},{"issue":"8","key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1128\/jvi.71.8.6011-6019.1997","article-title":"Immunodominant CD4+ T\u2010cell epitope within nonstructural protein 3 in acute hepatitis C virus infection","volume":"71","author":"Diepolder HM","year":"1997","journal-title":"J Virol"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30293"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200201)32:1<144::AID-IMMU144>3.0.CO;2-X"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50115"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021756"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1268"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2335981100"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403519101"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04079"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01177-06"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00292-7"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.23045"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(05)80019-8"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91126-X"},{"issue":"2","key":"e_1_2_7_33_2","first-page":"S4","article-title":"Abstracts of the 12th international symposium on viral hepatitis and liver disease","volume":"36","author":"Isvhld2006","year":"2006","journal-title":"J Clin Virol"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.09.005"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2006.09.010"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00302-9"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00447-X"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20408"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302751"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117662"},{"issue":"5","key":"e_1_2_7_41_2","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.4049\/jimmunol.162.5.3088","article-title":"Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans","volume":"162","author":"Livingston BD","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01537-06"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1114016"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20268"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.02.003"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.05.009"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.11.6372-6380.2003"},{"issue":"9","key":"e_1_2_7_48_2","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.4049\/jimmunol.161.9.4917","article-title":"Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model","volume":"161","author":"Encke J","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.4.1294"},{"issue":"5","key":"e_1_2_7_50_2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1073\/pnas.93.5.1759","article-title":"A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells","volume":"93","author":"Rosa D","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50474"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1353"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.024"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20839"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2007.00922.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2007.00922.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:31:10Z","timestamp":1695763870000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2007.00922.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,22]]},"references-count":53,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1365-2893.2007.00922.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2007.00922.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,22]]}}}